Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LB PHARMACEUTICALS INC Director's Dealing 2025

Sep 13, 2025

33183_dirs_2025-09-12_b67a01e6-2518-4532-a789-5c99f5b9ca5e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LB PHARMACEUTICALS INC (LBRX)
CIK: 0001691082
Period of Report: 2025-09-10

Reporting Person: Nussbaum Ran (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-09-10 Stock Option (Right to Buy) $15 A 22449 Acquired 2035-09-09 Common Stock (22449) Direct

Footnotes

F1: The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.